文献速递免疫规划慢病防控与筛查

重组带状疱疹疫苗在炎症性肠病患者中的有效性

Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
PubMed 文献 · Vaccine · 2021-06-16

本研究利用Explorys数据库开展回顾性队列研究,比较≥50岁炎症性肠病患者与一般人群接种重组带状疱疹疫苗后预防带状疱疹的效果。结果显示,接种疫苗可显著降低炎症性肠病患者带状疱疹发生率(OR 0.36,95%CI 0.23-0.56),但接种后患者风险仍高于接种的一般人群(OR 3.06,95%CI 1.87-5.02)。

要点

  • 炎症性肠病患者接种重组带状疱疹疫苗可显著降低带状疱疹风险。
  • 接种疫苗的炎症性肠病患者带状疱疹风险仍高于接种的一般人群。
  • 未接种的炎症性肠病患者带状疱疹风险显著高于一般人群。

核心结论

  • 重组带状疱疹疫苗可有效降低炎症性肠病患者带状疱疹风险。
  • 接种疫苗后炎症性肠病患者仍存在较高的带状疱疹风险。

研究设计与样本

  • 比较≥50岁炎症性肠病患者与≥50岁一般人群接种重组带状疱疹疫苗后带状疱疹发生率。

主要发现

  • ≥50岁炎症性肠病患者中接种带状疱疹疫苗(含减毒活疫苗或重组疫苗)比例低(112,200例中11,320例)。
  • 1,670例患者接种了重组带状疱疹疫苗。
  • 接种重组疫苗的炎症性肠病患者带状疱疹发生率OR 0.36(95%CI 0.23-0.56),一般人群OR 0.74(95%CI 0.59-0.92)。
  • 接种重组疫苗的炎症性肠病患者带状疱疹风险仍为接种一般人群的3倍(OR 3.06,95%CI 1.87-5.02)。
  • 未接种的炎症性肠病患者带状疱疹风险为一般人群的6倍(OR 6.21,95%CI 6.02-6.41)。

临床怎么用

  • 应重视炎症性肠病患者带状疱疹疫苗接种,以降低带状疱疹风险。
  • 接种后仍需关注炎症性肠病患者带状疱疹的残余风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with Inflammatory bowel disease (IBD) are at an increased risk of developing herpes zoster (HZ). The effectiveness of the recombinant zoster vaccine (RZV) in patients with IBD is unknown. METHODS: In this retrospective cohort study using Explorys (October 2017-April 2020; IBM Corporation, Somers, NY, USA), the effectiveness of RZV for the prevention of HZ in patients with IBD ≥ 50 years was compared to general population aged ≥ 50 years. Rates of de-novo HZ were compared between patients with IBD and the general population and stratified by number of RZV doses received. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). RESULTS: The overall proportion of IBD patients ≥ 50 years who received HZ vaccination with the live zoster vaccine (ZVL) or RZV was low (n = 11320, out of 112,200 IBD patients in the cohort). A total of 1670 patients received RZV. Receipt of the RZV resulted in a significantly lower rate of HZ in IBD patients (OR 0.36, 95% CI 0.23-0.56) compared to the general population (OR 0.74, 95% CI 0.59-0.92). However, despite vaccination, patients with IBD who received the RZV were still 3-times more likely to develop HZ during the study follow up period compared to the general population receiving the RZV (OR 3.06, 95% CI 1.87-5.02) and unvaccinated IBD patients were 6-times more likely to develop HZ compared to general population (OR 6.21, 95% CI 6.02-6.41). CONCLUSION: The recombinant zoster vaccine is effective in reducing the risk of HZ in patients with IBD compared to the general population. During our follow up period, patients with IBD, however, still remain at an increased risk for HZ despite vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kochhar GS, Desai A, Caldera DO F, et al. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease. Vaccine. 2021. PMID: 34140170. doi:10.1016/j.vaccine.2021.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。